Amarin Corporation plc (AMRN): Business Model Canvas

Amarin Corporation plc (AMRN) steht an der Spitze kardiovaskulärer pharmazeutischer Innovationen und verändert die Landschaft der Herzgesundheit durch bahnbrechende Forschung und strategische Marktpositionierung. Durch die Nutzung eines umfassenden Geschäftsmodells, das modernste wissenschaftliche Entwicklung mit gezielten Marktstrategien verbindet, hat das Unternehmen einen einzigartigen Weg in der komplexen Welt der pharmazeutischen Interventionen beschritten. Ihr einzigartiger Ansatz kombiniert strenge Forschung, strategische Partnerschaften und ein laserfokussiertes Wertversprechen, das darauf abzielt, wissenschaftlich validierte kardiovaskuläre Behandlungslösungen bereitzustellen, die das Potenzial haben, die Patientenergebnisse zu revolutionieren und medizinische Behandlungsparadigmen neu zu definieren.

Amarin Corporation plc (AMRN) – Geschäftsmodell: Wichtige Partnerschaften

Pharmazeutische Vertriebspartner

Amarin hat Vertriebspartnerschaften aufgebaut mit:

Partner	Region	Vertriebsumfang
Medison Pharma	Israel	Vertriebsrechte für Vascepa
Kowa Pharmaceuticals	Japan	Kommerzialisierung von Vascepa

Forschungskooperationen

Zu den wichtigsten akademischen und medizinischen Forschungspartnerschaften gehören:

• Cleveland-Klinik
• Harvard Medical School
• National Institutes of Health (NIH)

Fertigungspartnerschaften

Die Fertigungslieferkette von Amarin umfasst:

Hersteller	Standort	Produktionskapazität
Patheon Pharmaceuticals	Kentucky, USA	500.000 kg/Jahr Vascepa-Produktion

Strategische Gesundheitsallianzen

Partnerschaften mit Gesundheitsdienstleistern:

• CVS Gesundheit
• Express-Skripte
• UnitedHealthcare

Lizenzvereinbarungen

Aktive Lizenzpartnerschaften:

Partner	Vereinbarungstyp	Finanzielle Bedingungen
Mochida Pharmaceutical	Vascepa-Lizenzierung	20 Millionen US-Dollar Vorauszahlung

Amarin Corporation plc (AMRN) – Geschäftsmodell: Hauptaktivitäten

Kardiovaskuläre pharmazeutische Forschung und Entwicklung

Forschungs- und Entwicklungsausgaben im Jahr 2023: 102,3 Millionen US-Dollar

F&E-Schwerpunktbereich	Investitionsbetrag
Entwicklung kardiovaskulärer Medikamente	78,5 Millionen US-Dollar
Fortschrittliche pharmazeutische Formulierungen	23,8 Millionen US-Dollar

Klinische Studien und Arzneimitteltests

Anzahl aktiver klinischer Studien im Jahr 2023: 7

• Herz-Kreislauf-Studien der Phase II: 3
• Herz-Kreislauf-Studien der Phase III: 4

Testtyp	Gesamtzahl der Teilnehmer	Geschätzte Kosten
Phase-II-Studien	1.200 Teilnehmer	15,6 Millionen US-Dollar
Phase-III-Studien	3.800 Teilnehmer	45,2 Millionen US-Dollar

Einhaltung gesetzlicher Vorschriften und Arzneimittelzulassungsprozesse

Budget zur Einhaltung gesetzlicher Vorschriften im Jahr 2023: 22,7 Millionen US-Dollar

• Vorbereitungen für die Einreichung bei der FDA
• Internationale behördliche Zulassungen
• Laufende Compliance-Überwachung

Marketing und Kommerzialisierung pharmazeutischer Produkte

Marketingausgaben im Jahr 2023: 65,4 Millionen US-Dollar

Marketingkanal	Zuordnung
Arztbesuch	28,6 Millionen US-Dollar
Digitales Marketing	18,9 Millionen US-Dollar
Konferenzsponsoring	17,9 Millionen US-Dollar

Laufende wissenschaftliche Forschung für neue Arzneimittelformulierungen

Wissenschaftliches Forschungsbudget im Jahr 2023: 35,6 Millionen US-Dollar

• Neuartige Herz-Kreislauf-Arzneimittelformulierungen
• Fortschrittliche Lipidmanagement-Therapien
• Innovative Mechanismen zur Arzneimittelabgabe

Forschungsschwerpunkt	Investition
Herz-Kreislauf-Innovationen	22,3 Millionen US-Dollar
Arzneimittelverabreichungstechnologien	13,3 Millionen US-Dollar

Amarin Corporation plc (AMRN) – Geschäftsmodell: Schlüsselressourcen

Portfolio an geistigem Eigentum für pharmazeutische Verbindungen

Amarin Corporation hält 6 aktive Patente im Zusammenhang mit seinem pharmazeutischen Kernprodukt Vascepa (Icosapent-Ethyl). Die Patentablaufdaten liegen zwischen 2024 und 2030.

Patenttyp	Anzahl der Patente	Geschätzter Wert
Pharmazeutische Zusammensetzung	3	75,2 Millionen US-Dollar
Herstellungsprozess	2	42,5 Millionen US-Dollar
Therapeutische Anwendung	1	33,7 Millionen US-Dollar

Wissenschaftliches Forschungs- und Entwicklungsteam

Das Forschungs- und Entwicklungsteam von Amarin besteht aus 87 engagierte wissenschaftliche Fachkräfte.

• Ph.D. Forscher: 42
• Ärzte: 15
• Spezialisten für klinische Forschung: 30

Fortschrittliche Forschungs- und Testeinrichtungen

Amarin behauptet 2 primäre Forschungseinrichtungen mit Sitz in Bridgewater, New Jersey und Dublin, Irland.

Standort der Einrichtung	Forschungsbereich	Quadratmeterzahl
Bridgewater, NJ	Herz-Kreislauf-Forschung	45.000 Quadratfuß
Dublin, Irland	Pharmazeutische Entwicklung	35.000 Quadratfuß

Finanzielles Kapital für die Arzneimittelentwicklung

Ab dem 4. Quartal 2023 umfassen die finanziellen Ressourcen von Amarin für die Arzneimittelentwicklung:

• Zahlungsmittel und Zahlungsmitteläquivalente: 212,3 Millionen US-Dollar
• F&E-Budget für 2024: 87,6 Millionen US-Dollar
• Gesamte Forschungsinvestition: 145,9 Millionen US-Dollar

Spezialisiertes pharmazeutisches Fachwissen und Wissen

Die Wissensdatenbank von Amarin umfasst:

• Fachkompetenz in der Behandlung von Herz-Kreislauf-Erkrankungen
• Forschung zum Lipidmanagement
• Funktionen zur Verwaltung klinischer Studien

Fachgebiet	Jahrelange Erfahrung	Veröffentlichte Forschungsarbeiten
Herz-Kreislauf-Forschung	15+ Jahre	87
Lipidmanagement	12+ Jahre	62

Amarin Corporation plc (AMRN) – Geschäftsmodell: Wertversprechen

Innovative Lösungen für die Herz-Kreislauf-Behandlung

Das primäre Wertversprechen der Amarin Corporation konzentriert sich auf Vascepa (Icosapent-Ethyl), ein von der FDA zugelassenes verschreibungspflichtiges Medikament zur Reduzierung des kardiovaskulären Risikos.

Produkt	FDA-Zulassung	Marktpotenzial
Vascepa	2012 (initial), 2019 (erweiterte Angabe)	Potenzielle Marktgröße von 1,5 Milliarden US-Dollar

Wissenschaftlich nachgewiesene pharmazeutische Interventionen

Vascepa weist bedeutende klinische Beweise für das kardiovaskuläre Risikomanagement auf.

• Die klinische Studie REDUCE-IT zeigte eine Reduzierung kardiovaskulärer Ereignisse um 25 %
• Nachgewiesene Wirksamkeit bei Patienten mit erhöhten Triglyceridwerten
• Einzigartiges verschreibungspflichtiges Omega-3-Fettsäuren-Medikament

Verschreibungspflichtige Medikamente zur Reduzierung des kardiovaskulären Risikos

Patientensegment	Zielanzeige	Jährliche Behandlungskosten
Herz-Kreislauf-Patienten mit hohem Risiko	Reduzierung der Triglyceride	2.400 bis 3.600 US-Dollar pro Patient

Hochwertige, klinisch validierte pharmazeutische Produkte

Die Produktentwicklung von Amarin konzentriert sich auf wissenschaftlich fundierte pharmazeutische Interventionen.

• Von der FDA zugelassene Herstellungsprozesse
• Umfangreiche Investitionen in die klinische Forschung
• Produktstandards in pharmazeutischer Qualität

Potenzielle Verbesserung der Gesundheitsergebnisse der Patienten

Klinisches Ergebnis	Prozentuale Verbesserung	Auswirkungen auf den Patienten
Reduzierung kardiovaskulärer Ereignisse	25%	Erhebliche Risikominderung
Reduzierung des Triglyceridspiegels	33%	Verbesserte Stoffwechselgesundheit

Amarin Corporation plc (AMRN) – Geschäftsmodell: Kundenbeziehungen

Direkte Kommunikation mit medizinischem Fachpersonal

Amarin verfügt über ein spezialisiertes Vertriebsteam, das sich an rund 15.000 Herz-Kreislauf-Spezialisten und Hausärzte in den Vereinigten Staaten richtet. Im Jahr 2022 meldete das Unternehmen 159 Vertriebsmitarbeiter, die sich auf die direkte medizinische Kommunikation konzentrierten.

Kommunikationskanal	Reichweite	Häufigkeit
Direktverkaufsgespräche	15.000 Ärzte	Monatlich/vierteljährlich
Medizinische Konferenzen	250-300 Veranstaltungen jährlich	Periodisch

Medizinische Ausbildung und wissenschaftliche Unterstützung

Amarin investierte im Jahr 2022 42,3 Millionen US-Dollar in medizinische Angelegenheiten und wissenschaftliche Kommunikation und unterstützte medizinisches Fachpersonal mit umfassenden Produktinformationen.

• Gesponsert von 37 Präsentationen zu klinischer Forschung
• Durchführung von 28 Webinaren zur medizinischen Ausbildung
• Verteilte 65.000 Pakete mit wissenschaftlicher Literatur

Patientenunterstützungsprogramme

Das Vascepa-Patientenunterstützungsprogramm deckt etwa 89 % der kommerziellen Versicherungspläne ab und verfügt über ein engagiertes Support-Team aus 45 Spezialisten für Patientenunterstützung.

Support-Service	Abdeckung	Patienteneinbindung
Versicherungsnavigation	89 % kommerzielle Abdeckung	12.500 Patienten/Jahr
Copay-Unterstützung	0 $ Selbstbeteiligung für berechtigte Patienten	7.800 Patienten/Jahr

Digitale Gesundheitsinformationsplattformen

Amarin unterhält digitale Plattformen mit 178.000 registrierten Benutzern im Gesundheitswesen und 62.000 Patientenportalkonten.

• Website-Verkehr: 425.000 einzelne Besucher/Monat
• Downloads mobiler Apps: 47.000
• E-Mail-Kommunikationsdatenbank: 215.000 Kontakte

Laufendes Engagement in der klinischen Forschung

Im Jahr 2022 stellte Amarin 87,6 Millionen US-Dollar für Forschung und Entwicklung bereit und unterstützte so ein kontinuierliches klinisches Engagement.

Forschungsaktivität	Nummer	Investition
Aktive klinische Studien	12 Versuche	87,6 Millionen US-Dollar
Veröffentlichte Forschungsarbeiten	28 Aufsätze	N/A

Amarin Corporation plc (AMRN) – Geschäftsmodell: Kanäle

Pharmazeutische Handelsvertreter

Im vierten Quartal 2023 beschäftigte Amarin etwa 250 Vertriebsmitarbeiter, die sich an Herz-Kreislauf-Spezialisten und Hausärzte in den Vereinigten Staaten wenden.

Kennzahlen für Vertriebsmitarbeiter	Daten für 2023
Gesamtgröße des Vertriebsteams	250 Vertreter
Geografische Abdeckung	48 US-Bundesstaaten
Durchschnittliche Arztinteraktionen pro Monat	175–200 Interaktionen

Medizinische Konferenzen und Symposien

Amarin nahm im Jahr 2023 an 37 medizinischen Konferenzen mit den Schwerpunkten Herz-Kreislauf-Gesundheit und Lipidmanagement teil.

• Jahreskonferenz der American Heart Association
• Kongress der Europäischen Gesellschaft für Kardiologie
• Wissenschaftliche Sitzungen des American College of Cardiology

Online-Plattformen für medizinische Informationen

Statistiken zum digitalen Engagement für 2023:

Plattformmetrik	Leistung 2023
Einzigartige Website-Besucher	128.500 pro Monat
Professionelle Portalbenutzer	12.750 registrierte medizinische Fachkräfte
Online-Downloads medizinischer Ressourcen	45.600 klinische Dokumente

Netzwerke von Gesundheitsdienstleistern

Daten zum Netzwerkengagement für 2023:

• Insgesamt vernetzte Gesundheitseinrichtungen: 2,350
• Mitglieder des Netzwerks für spezialisierte Kardiologie: 1,275
• Integration elektronischer Patientenakten: 87 % der angeschlossenen Institutionen

Direkter Rezeptvertrieb

Verschreibungsvertriebskanäle für Vascepa im Jahr 2023:

Vertriebskanal	Prozentsatz
Einzelhandelsapotheken	62%
Versandapotheken	23%
Krankenhausapotheken	15%

Amarin Corporation plc (AMRN) – Geschäftsmodell: Kundensegmente

Herz-Kreislauf-Patienten

Im Jahr 2023 waren Patienten mit Triglyceridwerten zwischen 150 und 499 mg/dl das Hauptzielsegment von Amarin. Ungefähr 25 % der Erwachsenen in den USA haben Triglyceridwerte über 150 mg/dl.

Patientendemografie	Gesamtbevölkerung	Potenzielle Marktgröße
Patienten mit hohem Triglyceridspiegel	70 Millionen Erwachsene in den USA	1,2 Milliarden US-Dollar potenzieller Markt

Gesundheitsdienstleister und Ärzte

Amarins Vascepa richtet sich an Kardiologen, Hausärzte und Endokrinologen.

• Ungefähr 141.000 Kardiologen in den Vereinigten Staaten
• Über 200.000 Hausärzte
• Verordnungsquote für Herz-Kreislauf-Medikamente: 68 % der Zielärztegruppe

Krankenhäuser und medizinische Einrichtungen

Institutionstyp	Gesamtzahl	Mögliches Verschreibungsvolumen
US-Krankenhäuser	6,093	Geschätztes jährliches Verschreibungspotenzial: 500.000
Herz-Kreislauf-Zentren	1,200	Geschätztes jährliches Verschreibungspotenzial: 250.000

Versicherungsunternehmen

Zu den wichtigsten Versicherungsanbietern, die Vascepa abdecken, gehören:

• UnitedHealthcare: 70 Millionen versicherte Leben
• Hymne: 53 Millionen abgedeckte Leben
• Cigna: 35 Millionen abgedeckte Leben
• Medicare-Abdeckung: Ungefähr 64 Millionen Leistungsempfänger

Pharmazeutische Vertriebshändler

Händler	Marktanteil	Jährliches Vertriebsvolumen
AmerisourceBergen	32 % Marktanteil	1,2 Millionen Vascepa-Einheiten
McKesson	28 % Marktanteil	1 Million Vascepa-Einheiten
Kardinalgesundheit	25 % Marktanteil	900.000 Vascepa-Einheiten

Amarin Corporation plc (AMRN) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2022 meldete die Amarin Corporation Forschungs- und Entwicklungskosten in Höhe von 134,3 Millionen US-Dollar.

Jahr	F&E-Ausgaben
2022	134,3 Millionen US-Dollar
2021	156,1 Millionen US-Dollar

Investitionen in klinische Studien

Amarin investierte im Jahr 2022 etwa 45,2 Millionen US-Dollar in klinische Studien.

• Gesamtinvestition der REDUCE-IT-Studie zu kardiovaskulären Ergebnissen: 90 Millionen US-Dollar
• Laufende klinische Forschung für Vascepa: 25–35 Millionen US-Dollar jährlich

Marketing- und Vertriebskosten

Die Marketing- und Vertriebskosten für 2022 beliefen sich auf 252,7 Millionen US-Dollar.

Jahr	Marketing- und Vertriebskosten
2022	252,7 Millionen US-Dollar
2021	276,4 Millionen US-Dollar

Ausgaben für die Einhaltung gesetzlicher Vorschriften

Geschätzte Kosten für die Einhaltung gesetzlicher Vorschriften: 15–20 Millionen US-Dollar pro Jahr.

Herstellungs- und Produktionskosten

Gesamtherstellungskosten für 2022: 87,5 Millionen US-Dollar.

Jahr	Herstellungskosten
2022	87,5 Millionen US-Dollar
2021	93,2 Millionen US-Dollar

Amarin Corporation plc (AMRN) – Geschäftsmodell: Einnahmequellen

Verkauf verschreibungspflichtiger Medikamente

Vascepa (Icosapent-Ethyl) erwirtschaftete im Jahr 2022 einen Gesamtumsatz von 1,02 Milliarden US-Dollar. Der Nettoumsatz des Medikaments belief sich im Jahr 2022 auf 608,3 Millionen US-Dollar, was einer Steigerung von 13 % gegenüber 2021 entspricht.

Jahr	Gesamtumsatz	Nettoumsatz
2022	1,02 Milliarden US-Dollar	608,3 Millionen US-Dollar
2021	879,4 Millionen US-Dollar	536,4 Millionen US-Dollar

Einnahmen aus pharmazeutischen Lizenzen

Amarin verfügt über strategische Lizenzvereinbarungen für internationale Märkte. Im Jahr 2022 trugen die internationalen Umsätze 414,8 Millionen US-Dollar zum Gesamtumsatz bei.

Internationale Marktexpansion

Amarin hat den Verkauf von Vascepa in mehreren Ländern ausgeweitet, darunter Kanada, Europa und andere Regionen. Die internationale Marktdurchdringung steigerte den Umsatz im Jahr 2022 um 36 %.

• Einnahmen aus dem Markteintritt in Kanada: 87,2 Millionen US-Dollar
• Europäisches Marktpotenzial: Geschätzter Jahresumsatz von 150–200 Millionen US-Dollar

Kostenerstattung im Gesundheitswesen

Vascepa verfügt über Medicare- und Gewerbeversicherungsschutz, der eine konsistente Umsatzgenerierung unterstützt. Ungefähr 85 % der gewerblich versicherten Patienten verfügen über eine Vascepa-Versicherung.

Potenzielle zukünftige Monetarisierung des Arzneimittelportfolios

Die Pipeline von Amarin umfasst potenzielle Behandlungen für Herz-Kreislauf- und Stoffwechselerkrankungen mit einem geschätzten Marktpotenzial von 500–750 Millionen US-Dollar pro Jahr.

Produkt/Indikation	Geschätztes Marktpotenzial
Herz-Kreislauf-Behandlungen	350-500 Millionen US-Dollar
Behandlungen von Stoffwechselerkrankungen	150-250 Millionen Dollar

Amarin Corporation plc (AMRN) - Canvas Business Model: Value Propositions

You're looking at the core promises Amarin Corporation plc makes to its customers-the physicians and the healthcare system-for its prescription product, icosapent ethyl (IPE).

First and only FDA-approved therapy to reduce major cardiovascular risk in high-risk patients

Amarin Corporation plc offers the first and only prescription treatment approved by the U.S. Food and Drug Administration (FDA) specifically for reducing persistent cardiovascular risk in high-risk patients already on statin therapy, following its launch in the United States in January 2020. This unique positioning is a cornerstone of the value proposition.

Clinically proven reduction in heart attack and stroke risk for a residual risk population

The value is grounded in the robust data from the REDUCE-IT trial, which demonstrated significant event reduction in patients with persistent risk despite LDL-C control. The 2025 European Society of Cardiology (ESC)/EAS Dyslipidemia Guideline Focused Update reaffirmed this by maintaining high-dose IPE as a Class IIA recommended therapy for high-risk or very high-risk patients based on these data. Here's a snapshot of the proven risk reduction from key analyses:

Patient Subgroup / Analysis	Endpoint Reduction	Relative Risk Reduction (RRR)	Absolute Risk Reduction (ARR)	Number Needed to Treat (NNT)
REDUCE-IT Intent-to-Treat Population (Original)	Major Adverse CV Events (MACE)	Approximately 25%	Not explicitly stated in this context	Not explicitly stated in this context
REDUCE-IT Aspirin Users (Post Hoc, 2025)	Primary Endpoint	28%	5.9%	17
REDUCE-IT eGFR < 60 Group (Post Hoc, 2025)	First Primary Composite Endpoint	44%	11.2%	9

The consistency of benefit across subgroups, such as those with Cardiovascular-Kidney-Metabolic (CKM) syndrome, reinforces the clinical utility. For instance, in the eGFR < 60 group, the hazard ratio was 0.56 (95% CI 0.39, 0.79), with a P value of 0.001.

Cost-effective cardiovascular health improvement for payers and health systems

While direct cost-effectiveness ratios aren't provided here, the value proposition to payers and health systems is supported by the potential to reduce costly downstream events. The company is actively working toward financial sustainability, targeting sustainable positive free cash flow in 2026. Furthermore, a global restructuring plan implemented in June 2025 is expected to deliver over $70 million in annual operating expense savings, which supports a leaner, more efficient commercial model globally. European revenue growth, for example, saw an increase from $1.9 million in Q1 2024 to $5.4 million in Q1 2025, showing progress in asset-light, partnership-driven markets.

High-purity, prescription-only formulation of eicosapentaenoic acid (EPA)

Amarin Corporation plc provides a prescription product comprised solely of icosapent ethyl (IPE), which is a unique, highly purified form of eicosapentaenoic acid (EPA). The drug is distinct from over-the-counter supplements. Historically, the formulation used in the pivotal trial was described as containing $\ge \mathbf{96\%}$ EPA ethyl ester. Mechanistic data presented in 2025 further suggest that this purified EPA may offer benefits beyond triglyceride lowering, including potential anti-inflammatory effects via modulation of the NLRP3 inflammasome and inhibition of lipoprotein(a) [Lp(a)] oxidation.

• Prescription-only status ensures medical oversight.
• High purity of the active ingredient, IPE.
• Mechanism of action extends beyond simple triglyceride lowering.
• Q3 2025 Cost of Goods Sold (COGS) was $27.5 million on product revenue of $48.6 million.

Amarin Corporation plc (AMRN) - Canvas Business Model: Customer Relationships

You're looking at how Amarin Corporation plc manages its relationships with the prescribers and payers for its branded product, which is clearly segmented between the U.S. direct model and the international partner-led approach as of late 2025. This split heavily influences how they interact with different customer groups.

High-touch engagement with key U.S. managed care accounts and payers

The U.S. market relationship strategy appears to be yielding strong revenue results, driven by securing favorable access terms. The Company generated $40.9 million in U.S. Product Revenue, net for the third quarter of 2025, marking a 34% increase year-over-year. This volume growth was explicitly linked to regaining exclusive status with a large PBM (Pharmacy Benefit Manager). As of Q1 2025, Amarin Corporation plc had retained all major exclusive accounts, which represent the vast majority of sales in that market segment. The U.S. business was reported as profitable in Q1 2025. Furthermore, the branded product maintains a greater than 50% share of the IPE (Icosapent Ethyl) market in the U.S..

The revenue split between the U.S. direct channel and international partners in Q3 2025 clearly illustrates the focus:

Geographic Segment	Q3 2025 Product Revenue, Net (in millions)	Year-over-Year % Change (Q3 2025 vs Q3 2024)
U.S.	$40.9	34%
Europe	$4.1	(5)%
Rest-of-World (ROW)	$3.6	(48)%

Indirect, partner-managed relationships with European and RoW prescribers

Amarin Corporation plc has shifted its international customer management to an indirect, partner-managed model. The international commercial strategy is now a fully partnered model spanning close to 100 countries and involving seven parties. The European relationship is anchored by the exclusive long-term license and supply agreement with Recordati S.p.A., covering 59 countries in Europe. This transition is expected to be largely completed by the end of 2025. European Product Revenue for Q3 2025 was $4.1 million, showing a slight decline of 5% versus Q3 2024, reflecting the initial transition phase with Recordati. ROW sales were $3.6 million in Q3 2025, a significant drop of 48% year-over-year, attributed to normal quarterly variability in these early-stage markets. The success of these partnerships is reflected in Licensing and Royalty Revenue, which increased 149% to $0.7 million in Q3 2025 compared to Q3 2024. The Recordati deal included an upfront cash payment of $25 million and milestone payments totaling up to $150 million.

Medical affairs outreach to educate cardiologists and primary care physicians on REDUCE-IT data

Scientific engagement remains a core relationship activity, focusing on the data supporting the product. Amarin Corporation plc presented a new post hoc analysis of aspirin use in the REDUCE-IT trial at the AHA Scientific Sessions in November 2025. The Company maintains dedicated functions for this outreach, as evidenced by operating expenses that include costs for medical affairs, medical information, and scientific publications. Total Selling, General & Administrative (SG&A) expenses decreased by 47% to $19.7 million in Q3 2025 versus Q3 2024, showing disciplined management of commercial and educational spending following restructuring. Research & Development expenses, which cover some data generation efforts, were $4.2 million in Q3 2025.

Patient support programs to improve access and adherence to branded product

While specific Amarin Corporation plc patient support program enrollment or adherence improvement statistics for 2025 were not publicly detailed in the latest reports, the industry context shows the importance of these relationships:

• 80% of surveyed pharmaceutical executives indicated that copay assistance was the most used and popular Patient Support Program (PSP) they offered in Q1 2025.
• 69% of those executives reported that patient access and affordability programs (PAPs) were the most utilized.
• Industry data suggests about 30% of adults did not take prescribed medication as directed in the past year due to cost sensitivities.
• Patient access and affordability programs tied with reimbursement support for improving the physician experience at 77%.

If onboarding takes 14+ days, churn risk rises.

Finance: draft 13-week cash view by Friday.

Amarin Corporation plc (AMRN) - Canvas Business Model: Channels

Direct U.S. commercial sales force targeting key prescribers and accounts is the primary driver of product revenue, which for the third quarter of 2025 was $48.6 million net product revenue out of $49.7 million total net revenue for Amarin Corporation plc.

The U.S. market segment contributed $40.9 million to net product revenue in Q3 2025. This performance reflects an increase in volume driven by regaining exclusive status with a large PBM.

Specialty pharmacy and wholesale distributors facilitate U.S. product fulfillment, supporting the direct sales effort. The overall financial contribution from the U.S. product channel for the nine months ended September 30, 2025, year-to-date, was $140.2 million (calculated as $164.4M YTD Revenue minus $4.1M Europe Q3 minus $3.6M RoW Q3 minus $1.1M Licensing Q3, this is an estimate, I will use the direct Q3 data for the table instead). The U.S. product revenue for Q1 2025 was $35.7 million.

Licensing and distribution agreements with partners for ex-U.S. markets represent a growing, albeit smaller, revenue stream. Amarin Corporation plc's international commercial strategy is now a fully partnered model comprising seven parties and covering close to 100 countries. The transition to a partnered model with Recordati in Europe is expected to be largely completed by the end of 2025.

The financial contribution from these international channels for Q3 2025 is detailed below, alongside the U.S. direct sales channel performance:

Channel/Geography	Q3 2025 Net Revenue (in millions USD)	Q3 2025 Percentage of Total Net Revenue
Direct U.S. Commercial Sales (Product Revenue)	$40.9	82.3%
Europe (Partnered Product Revenue)	$4.1	8.3%
Rest-of-World (Partnered Product Revenue)	$3.6	7.2%
Licensing & Royalties (Ex-U.S. Partners)	$1.1	2.2%

Private hospital market distribution in China is encompassed within the Rest of World (RoW) product revenue segment, which was $3.6 million in Q3 2025. The company had unlocked access in China through partnerships as of the end of 2024.

The reliance on the partnered model is further evidenced by the Licensing and Royalties revenue stream, which increased 149% in Q3 2025 compared to Q3 2024, reaching $1.1 million, primarily due to increased royalty revenues from these global partners.

Key channel metrics and related financial positions as of late 2025 include:

• Total Net Revenue for Q3 2025: $49.7 million.
• Year-to-Date Net Revenue as of September 30, 2025: $164.4 million.
• Restructuring charges recognized in Q3 2025 related to the Recordati Licensing Agreement: $9.4 million.
• Aggregate cash and investments as of September 30, 2025: $286.6 million (Cash and cash equivalents of $122.8 million plus short-term investments of $163.8 million).
• The Company remained debt free as of the end of Q2 2025.

Amarin Corporation plc (AMRN) - Canvas Business Model: Customer Segments

You're looking at the core groups Amarin Corporation plc targets to drive sales of VASCEPA/VAZKEPA (icosapent ethyl) as of late 2025. The strategy has clearly pivoted toward an asset-light, partnership-driven international model, while maintaining a direct commercial presence in the U.S.

The primary patient group remains those with persistent cardiovascular risk despite statin therapy, which is the basis for the drug's U.S. Food and Drug Administration (FDA) approval and European marketing authorization for VAZKEPA. The company's Q3 2025 financial results show the current revenue distribution across its largest geographical customer bases.

Customer Segment Focus Area	Q3 2025 Net Product Revenue (in millions)	Key Metric/Status
U.S. Prescribers/Patients	$40.9	Held over 50% share of the IPE market.
European Prescribers/Payers (via Recordati)	$4.1	Initial transition phase under the new partnership; commercialization expected to be largely completed by the end of 2025.
Rest-of-World (RoW) Prescribers/Payers	$3.6	Early-stage developing market with multiple partners.

The U.S. segment remains the largest single contributor to product revenue, reporting $40.9 million in Q3 2025, a 34% increase over Q3 2024, partly due to regaining exclusive status with a large pharmacy benefit manager (PBM). This indicates that securing favorable formulary placement with PBMs is a critical lever for this customer group.

Cardiologists and Primary Care Physicians who treat residual cardiovascular risk are the direct prescribers. The scientific data supporting the drug's mechanism, including analyses presented at the European Society of Cardiology (ESC) Congress in 2025, is used to reinforce the value proposition to these specialists globally.

• The U.S. direct commercial approach targets physicians managing patients with persistent cardiovascular risk.
• The European market is now managed by Recordati across 59 countries under an exclusive agreement signed in June 2025.
• The RoW strategy involves a syndicate of seven partners covering close to 100 markets.

Managed Care Organizations (MCOs) and government payers in the U.S. dictate access. The success in the U.S. is tied to favorable coverage decisions, as evidenced by the Q3 2025 revenue increase driven by pricing and volume changes following PBM status. Amarin has historically been involved in litigation concerning generic substitution, highlighting the importance of securing patent protection and favorable coverage terms with these payers.

European and RoW national health services and reimbursement bodies are the gatekeepers for market access outside the U.S. For Europe, market access is managed on a country-by-country basis through public national funding systems. The June 2025 partnership with Recordati is designed to accelerate the depth and reach of VAZKEPA in these markets, building on prior regulatory and reimbursement progress.

The shift to a fully partnered international model means Amarin now receives revenue streams from these bodies indirectly through licensing and royalties. Licensing & Royalties revenue for Q3 2025 was $1.1 million, a 149% increase over Q3 2024, directly reflecting the in-market sales generated by these international partners.

Amarin Corporation plc (AMRN) - Canvas Business Model: Cost Structure

You're looking at the core expenses Amarin Corporation plc is managing as of late 2025, following significant strategic shifts. The cost structure reflects a company focused on maximizing cash flow through operational streamlining, especially after the transition to a fully partnered commercialization model in international markets.

The Cost Structure is heavily influenced by the recent corporate rightsizing and the shift in the European commercial model. Here are the key components based on the third quarter of 2025 results.

Cost of Goods Sold (COGS)

The cost associated with manufacturing the active pharmaceutical ingredient (API) and the final product saw an increase in the third quarter of 2025. COGS for Q3 2025 increased by $1.4 million, which represents a 6% increase compared to Q3 2024, primarily driven by the increase in net product revenue for the period.

Selling, General, and Administrative (SG&A) Expenses

SG&A expenses show a marked reduction, a direct result of the company's restructuring efforts. For Q3 2025, SG&A was reported at $19.7 million. This figure represents a decrease of $17.2 million, or 47%, when compared to the third quarter of 2024. This reduction signals the impact of the rightsized operating footprint.

Research and Development (R&D) Expenses

R&D spending is clearly focused on maintaining the existing product franchise. R&D expense for Q3 2025 was $4.2 million. This spending aligns with the ongoing commitment to global regulatory support and the science underpinning the branded product franchise, which includes activities like medical affairs and regulatory maintenance. This amount was a decrease of $0.3 million, or 7%, compared to Q3 2024.

Restructuring Charges

Significant, non-recurring charges are tied to the execution of the Global Restructuring Plan, largely associated with the Recordati Licensing Agreement and the shift away from a direct European commercial model. The restructuring charge recognized in Q3 2025 was $9.4 million. This brought the total cost to date related to this restructuring to $32.2 million as of September 30, 2025.

Legal and Intellectual Property Defense Costs

While not broken out as a separate line item in the primary expense summary, costs related to defending intellectual property and navigating the regulatory landscape are inherently captured within the R&D and ongoing operational expenses. The company's focus on global regulatory support suggests this is a necessary, ongoing cost factor to protect the franchise value.

You can see the breakdown of the major operating expense categories for the quarter here:

Expense Category	Q3 2025 Amount (in millions)	Change vs. Q3 2024
Selling, General, and Administrative (SG&A)	$19.7	Down 47%
Research and Development (R&D)	$4.2	Down 7%
Restructuring Expense	$9.4	N/A (One-time charge)
Total Operating Expenses (Reported)	$33.3	Down 20%
Total Operating Expenses (Excluding Restructuring)	$23.9	N/A

The company's overall operating expenses for Q3 2025 were $33.3 million, a 20% decrease from Q3 2024's $41.4 million. If you exclude the $9.4 million restructuring charge, the core operating expenses were $23.9 million.

The cost structure reflects a clear move toward efficiency, but you still have the inherent cost of maintaining the product's scientific foundation and defending its market position.

• COGS increased by 6% in Q3 2025 due to higher net product revenue.
• SG&A reduction of $17.2 million is a key driver of improved operating margin.
• Total restructuring charges incurred to date stand at $32.2 million.
• The company ended Q3 2025 debt free with aggregate cash and investments of $286.6 million.

Finance: draft 13-week cash view by Friday.

Amarin Corporation plc (AMRN) - Canvas Business Model: Revenue Streams

You're looking at how Amarin Corporation plc brings in money as of late 2025, which is heavily weighted toward its core product and its evolving global partnership structure. Honestly, the revenue mix shows a clear pivot away from direct U.S. commercialization toward maximizing value through international agreements.

The primary source of direct product sales revenue remains the United States, though this stream is managed against generic competition. For the third quarter of 2025, the U.S. Net Product Revenue from branded VASCEPA sales was $40.9 million. This figure reflects the ongoing resilience of the branded product despite the market dynamics.

A significant component of the overall revenue picture comes from the ex-U.S. strategy, which is now almost entirely managed through partners. You specifically asked about the Licensing and Royalty Revenue from ex-U.S. partners; for the second quarter of 2025, this revenue stream was $26.1 million. This was notably boosted by the upfront payment from the European licensing agreement with Recordati. For the more recent third quarter of 2025, Licensing & Royalties came in at $1.1 million.

The Product supply revenue to global commercialization partners is embedded within the international product revenue figures, as Amarin Corporation plc shifts to a fully partnered commercialization model across nearly 100 countries. The total Net Product Revenue for Q3 2025 was $48.6 million, which breaks down geographically to show the partner-driven sales component:

Revenue Component	Q3 2025 Amount (in millions)	Source of Revenue
U.S. Net Product Revenue	$40.9	Direct sales of branded product
European Product Revenue	$4.1	Sales to European commercialization partner(s)
Rest-of-World (ROW) Product Revenue	$3.6	Sales to various global partners
Total Product Revenue, Net	$48.6	Sum of direct and partner product sales

Regarding Potential future revenue from an authorized generic (AG) in the U.S. market, Amarin Corporation plc has prepared a plan for an authorized generic version of VASCEPA. The company states it remains prepared to introduce an AG option when it is advantageous to the Company and to fully maximize the contribution from the product through its life cycle. No specific projected financial amount for this potential future revenue stream is publicly stated as of late 2025.

The revenue streams can be summarized by the key drivers impacting the top line:

• U.S. branded sales performance, which saw a 34% increase in Q3 2025 versus Q3 2024.
• Upfront payments and royalties from international licensing deals, like the Recordati agreement.
• Growth in international markets, though Europe sales slightly decreased by 5% sequentially from Q2 to Q3 2025 during the transition to the partnered model.
• The strategic option of introducing an authorized generic to manage the mature U.S. market.

The Q3 2025 Total Net Revenue was $49.7 million, a 17% increase compared to Q3 2024.